LYEL
NASDAQLyell Immunopharma Inc.
Website
News25/Ratings12
News · 26 weeks54-64%
2025-10-262026-04-19
Mix2690d
- Insider13(50%)
- SEC Filings6(23%)
- Other3(12%)
- Analyst2(8%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form EFFECT filed by Lyell Immunopharma Inc.EFFECT - Lyell Immunopharma, Inc. (0001806952) (Filer)
- ANALYSTNeedham initiated coverage on Lyell Immunopharma with a new price targetNeedham initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $44.00
- PRLyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the webcast will be available on the Company's website following the presentation date. About Lyell Lyell is a
- SECSEC Form S-3 filed by Lyell Immunopharma Inc.S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)
- INSIDERSEC Form 4 filed by Chief Fin. and Bus. Officer Shah Smital4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shah Smital3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- SECSEC Form S-8 filed by Lyell Immunopharma Inc.S-8 - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECSEC Form 10-K filed by Lyell Immunopharma Inc.10-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECLyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsPatient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate
- INSIDERLarge owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERLarge owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- ANALYSTCitizens initiated coverage on Lyell Immunopharma with a new price targetCitizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00
- SECSEC Form 8-K filed by Lyell Immunopharma Inc.8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerClosing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its Pi
- PRLyell Immunopharma Announces Participation in March Investor ConferencesSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern TimeCitizens Life Science Conference on Tuesday, March 10, 2026, in Miami,
- INSIDERPresident and CEO Seely Lynn sold $174,372 worth of shares (7,455 units at $23.39), decreasing direct ownership by 9% to 74,266 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Operating Officer Hill Stephen J. sold $28,910 worth of shares (1,236 units at $23.39), decreasing direct ownership by 6% to 17,795 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. sold $39,085 worth of shares (1,671 units at $23.39), decreasing direct ownership by 9% to 16,938 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- PRLyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaPiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line settingThe pivotal single-arm trial, PiNACLE, evaluating ronde-cel in the third- or later-line setting is ongoing with BLA submission expected in 2027Site activation for both PiNACLE – H2H and PiNACLE are underway in the United States, Canada and Australia SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen recept
- INSIDERChief Operating Officer Hill Stephen J. was granted 4,000 shares and sold $2,520 worth of shares (109 units at $23.12), increasing direct ownership by 26% to 19,031 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. was granted 4,000 shares and sold $3,399 worth of shares (147 units at $23.12), increasing direct ownership by 26% to 18,609 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERPresident and CEO Seely Lynn was granted 20,000 shares and sold $10,127 worth of shares (438 units at $23.12), increasing direct ownership by 31% to 81,721 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Meltz Mark A4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERVP, Corporate Controller Bulis Veronica Sanchez was granted 8,750 shares and sold $5,872 worth of shares (254 units at $23.12), increasing direct ownership by 119% to 15,637 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)